文献速递冠心病心律失常

多支血管PCI与CABG术后临床显著房颤发生率比较:全国性观察研究

Incidence of post-procedural atrial fibrillation after multivessel percutaneous coronary intervention versus coronary artery bypass grafting: a nationwide observational study
RSS 订阅 · Open Heart

基于瑞典全国注册数据,纳入慢性冠脉综合征行多支血管PCI(4471例)或孤立CABG(2232例)的患者,比较术后90天内临床显著房颤(以新启动口服抗凝且持续至9个月为代理定义)的发生率。结果显示CABG术后房颤发生率显著高于MV-PCI(5.7% vs 0.6%,调整风险比15.02)。

要点

  • CABG术后临床显著房颤发生率5.7%,MV-PCI仅0.6%,调整后风险比达15.02。
  • 90天全因死亡和大出血在两组间无显著差异,心肌梗死更多见于MV-PCI,卒中更多见于CABG。
  • 采用口服抗凝起始并持续作为房颤代理定义,可能低估未接受抗凝的房颤事件。

核心结论

  • 以口服抗凝治疗起始并持续为代理定义的临床显著术后房颤,在CABG术后发生率 nearly tenfold 高于MV-PCI,多因素调整后关联依然稳健。
  • 两组90天临床结局差异不大,需谨慎解读。

研究设计与样本

  • 全国性观察性研究,分析瑞典冠状动脉造影和血管成形术注册及瑞典处方药注册数据。
  • 共纳入4471例行MV-PCI和2232例行CABG的患者。

主要发现

  • 术后90天临床显著房颤发生率:MV-PCI组0.6%,CABG组5.7%(调整风险比15.02;95% CI 8.72至25.87;p<0.001)。
  • 90天全因死亡和大出血在两组间无显著差异。
  • 心肌梗死更常见于MV-PCI组(1.1% vs 0.4%),卒中更常见于CABG组(0.6% vs 0.3%)。
  • MV-PCI患者年龄更大、合并症更多,而CABG患者糖尿病比例更高、冠状动脉病变更广泛。

关键数值与推荐

  • 临床显著术后房颤定义为术后3个月内新启动口服抗凝药且持续至9个月。
  • 主要结局为术后90天房颤发生率;次要结局包括卒中、心肌梗死、大出血和全因死亡。

临床怎么用

  • CABG术后应警惕临床显著房颤的发生,MV-PCI术后发生率较低但仍需监测。
  • 术后房颤的识别可结合口服抗凝起始情况,但需注意代理定义的局限性。

局限性

  • 观察性设计,残余混杂可能影响因果推断。
  • 房颤定义基于口服抗凝处方代理,可能漏诊未抗凝的房颤或过度识别其他抗凝指征。
  • 两组患者基线特征存在差异,尽管多因素调整后关联稳健。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background Postoperative atrial fibrillation (AF) is a common complication after coronary artery bypass grafting (CABG) but is less well characterised after multivessel percutaneous coronary intervention (MV-PCI). With the increasing use of MV-PCI, we compared the incidence and clinical implications of clinically significant post-procedural AF following MV-PCI versus CABG. Methods In this nationwide observational study, we analysed data from the Swedish Coronary Angiography and Angioplasty Registry and the Swedish Prescribed Drug Register. We included all patients in Sweden with chronic coronary syndrome who underwent MV-PCI or isolated CABG between August 2013 and October 2020, excluding those with prior AF or oral anticoagulant (OAC) use in the preceding year. Clinically significant post-procedural AF was defined using a treatment-based proxy: a new OAC dispensation within 3 months after the procedure, with persistence at 9 months. The primary outcome was post-procedural AF incidence at 90 days; secondary outcomes were stroke, myocardial infarction, major bleeding and all-cause mortality. Results A total of 4471 patients undergoing MV-PCI and 2232 undergoing CABG were included. Post-procedural AF occurred in 0.6% after MV-PCI and 5.7% after CABG (adjusted risk ratio 15.02; 95% CI 8.72 to 25.87; p<0.001). MV-PCI patients were older and had more comorbidities, whereas CABG patients had higher rates of diabetes and more extensive coronary disease. At 90 days, all-cause mortality and major bleeding did not differ significantly. Myocardial infarction was more common after MV-PCI (1.1 vs 0.4%), whereas stroke was more frequent after CABG (0.6 vs 0.3%). Conclusions Clinically significant post-procedural AF, defined by initiation and persistence of OAC therapy, was nearly tenfold more common after CABG than after MV-PCI. This association remained robust after multivariable adjustment for demographics, comorbidities and angiographic/severity-related factors. Differences in clinical outcomes were modest and should be interpreted cautiously.

来源:Open Heart,查看原文。版权归原作者所有。

引用

  1. Open Heart:Incidence of post-procedural atrial fibrillation after multivessel percutaneous coronary intervention versus coronary artery bypass grafting: a nationwide observational study

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。